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Abstract It has previously been suggested that volume-regu-
lated anion channels (VRACs) and store-operated channels
(SOCs) interact with each other according to their expected
colocalization in the plasma membrane of LNCaP cells. In or-
der to study interactions between these two channels, we used
2-aminoethoxydiphenyl borate (2-APB) as a regular SOC in-
hibitor. Surprisingly 2-APB reduced VRAC activity in a dose-
dependent manner (IC50 = 122.8 WM), but not 2,2-diphenyltetra-
hydrofuran (a structural analog of 2-APB). This e¡ect was also
present in keratinocytes. We conclude that 2-APB is an inhib-
itor of the VRAC family, and is also a potent tool to study the
SOC^VRAC interaction in LNCaP cells.
4 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The volume-regulated anion channel (VRAC) is a ubiqui-
tous type of ion channel that plays a pivotal role in regulatory
volume decrease (RVD), a process by which cells control their
volume (for reviews, see [1^3]). One of the most important
discrepancies between the data on VRACs studied on di¡erent
cellular models concerns how these channels are regulated by
Ca2þ ions [4^6].
In our previous study [7] we addressed the hypothesis of a
functional link between plasma membrane VRACs, which
carry Cl3 current activated by hypotonic cell swelling
(ICl; swell), and the store-operated channels (SOCs), which are
activated in response to the depletion of intracellular Ca2þ
stores in prostate cancer epithelial cells. Indeed, the activation
of SOCs resulted in a signi¢cant inhibition of ICl; swell. We
concluded that interaction between VRACs and Ca2þ occurs
in the microdomains of the inner surface of the membrane,
which are not accessible to changes in global intracellular
calcium concentration.
The original aim of the present work was to further explore
the regulation of VRACs by the most universal second mes-
senger, Ca2þ, using the widely used inhibitor of SOCs and
inositol 1,4,5-triphosphate (IP3) receptors, 2-aminoethoxydi-
phenyl borate (2-APB) [8,9].
Unexpectedly (using patch-clamp, £uorescent Ca2þ mea-
surement and £ow cytometry techniques), we found that
2-APB may inhibit VRACs independently of its well-known
e¡ects on intracellular calcium signaling. Our study is the ¢rst
to show that 2-APB may be a direct inhibitor of VRACs.
Interestingly, this e¡ect of 2-APB seems to be speci¢c for
volume-activated chloride channels, since it was previously
reported that the Ca2þ-activated chloride current was not af-
fected in Xenopus oocytes [10]. We demonstrate this inhibitory
e¡ect of 2-APB on VRACs using two di¡erent cellular mod-
els: prostate epithelial cancer cells LNCaP, and human kera-
tinocytes HaCaT, thereby suggesting the ubiquitous nature of
2-APB e¡ect on VRACs. Moreover, this inhibitory 2-APB
e¡ect on VRACs was able to impair the normal RVD process.
Therefore, the inhibition of VRACs described in our study is
a new 2-APB property that promises to provide a powerful
pharmacological tool for studying volume-regulated channels,
the pharmacology of which is known to be rather poor.
2. Materials and methods
The culture of LNCaP cells and patch-clamp procedures (including
intra- and extracellular solution compositions) are the same as previ-
ously described [7]. The estimations of the changes in cell volume
during the RVD process were performed on a FACScalibur £ow
cytometer (Becton-Dickinson, San Jose, CA, USA) with the use of
‘Q Cell Quest’ software for data analysis [11]. The light-scatter chan-
nels were set on linear gains. Cells in suspension in normal or Hypo-
TEA solutions were gated for forward-angle scatters and 5000 par-
ticles of each gated population were analyzed.
Fluorescence [Ca2þ]in measurements were conducted on fura-2AM
(5 WM) loaded (45 min) LNCaP cells using a photomultiplier-based
system (Photon Technologies, Princeton, NJ, USA) and double wave-
length (340 and 380 nM) excitation protocol to quantify the absolute
value of Ca2þ concentration [12].
3. Results
3.1. ICl; swell is sensitive to 2-APB application
As described in previous studies, the application of hypo-
tonic external solution induced development of ICl; swell in
LNCaP cells. This current reached its maximal amplitude in
5^10 min and remained at this steady state as long as the cells
were superfused with hypotonic solution [13]. In Fig. 1A, a
100 WM 2-APB containing hypotonic solution was applied
after full development of ICl; swell in a representative cell.
2-APB application induced a drastic decrease in ICl; swell am-
plitude. In order to check how 2-APB modi¢ed ICl; swell elec-
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trophysiological properties, the same cell was subjected to a
ramp protocol as presented in Fig. 1B (inset). Resulting cur-
rents from this protocol are presented in Fig. 1B: currents
before (ctrl) and after (2-APB) 2-APB application exhibited
similar outward recti¢cation properties. As shown by corre-
sponding I/V relationships directly derived from previous
ramps, 2-APB exhibited a voltage-dependent VRAC block:
the rate of ICl; swell inhibition was slightly higher for negative
potentials than for positive ones (Fig. 1C). So, at 3100 mV
and +100 mV, the inhibition rates by 100 WM 2-APB were
55.6Q 6.8% and 39.2Q 3.7% respectively (n=8).
As a further demonstration of 2-APB as an ICl; swell inhib-
itor, we also investigated whether or not 2-APB would impair
the RVD process. RVD is the physiological consequence of
ICl; swell activation during hypotonic challenge. This experi-
ment is presented in Fig. 1D: the cell volume increase led to
the ICl; swell activation, which permitted the cells to recover
their normal volume. Cells pre-treated for 30 min with 100
WM 2-APB and exposed to a 2-APB containing hypotonic
solution exhibited a quite di¡erent response compared to con-
trol ones. 2-APB exposure was seen to be accompanied by an
exaggerated volume increase, reaching the maximal value of
35% (26.7% in control) after 1.5 min exposure to hypotonic
solution. After that, cells began to recover their normal value,
but this process was not complete after 10 min and cell vol-
ume remained slightly higher (17.9% volume increase com-
pared to 12% in control).
2-APB was previously shown to exhibit a strong inhibitory
e¡ect on IP3 receptor, transient receptor potential channels
and potassium channels [8,9]. However, in order to assess
whether VRAC are speci¢cally blocked by 2-APB, we used
a previously described molecule, 2,2-diphenyltetrahydrofuran
(DPTHF), exhibiting the same e¡ect as 2-APB on IP3 recep-
tors [8]. Results of DPTHF application on VRAC are sum-
Fig. 1. 2-APB inhibits ICl; swell in LNCaP cells. A: ICl; swell development after exposure to hypotonic extracellular solution (at time 0) observed
at +50 and 350 mV (circles), and resulting inhibition after 100 WM 2-APB exposure (down triangles) in a representative cell. B: ICl; swell traces
observed in control conditions (ctrl) or after 100 WM 2-APB application (2-APB); inset: pulse protocol. C: I/V plots derived from ramp traces
shown in B; inset: voltage dependence of the inhibition. D: RVD process in LNCaP cells (5000 cells at each point) exposed to standard (dark
gray bars) or 100 WM 2-APB supplemented hypotonic solution (light gray bars).
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marized in Fig. 3C: perfusing the cells previously exposed to
hypotonic challenge with a 100 WM and 1 mM DPTHF con-
taining hypotonic solution led to only a minor decrease in
current amplitude of 10.2 Q 4.8% for 1 mM and 100 WM,
leading to a small increase in ICl; swell amplitude of 5.6 Q
6.9%. These results have to be compared with those of
2-APB corresponding to a 44.4Q 3 and 91.7 Q 1.6% decrease
in VRAC-associated current after applications of 100 WM and
1 mM 2-APB respectively. These results argue in favor of a
direct action of 2-APB: a slight structural modi¢cation of
2-APB giving DPTHF, which exhibits the same e¡ects on
IP3 receptors as 2-APB, strongly impairing its action.
3.2. Properties of ICl; swell inhibition by 2-APB
All previous experiments were carried out with the standard
100 WM 2-APB concentration, which is known to completely
inhibit SOC. In order to assess whether ICl; swell inhibition by
2-APB was also maximal at 100 WM, we did further experi-
ments with various 2-APB concentrations. Our results are
summarized in Fig. 2A: applications of 10, 50, 100, 200,
500, 1000, 2000 WM 2-APB led to respective decreases in
ICl; swell amplitude at +100 mV of 10.7Q 2.5, 30.4Q 4.3,
44.4Q 3, 65.4Q 3, 76.5 Q 1.9, 91.7Q 1.6, 91.4Q 2.6% (n=4 for
each concentration). We determined the concentration of half-
maximal blockade (IC50) and the level of maximal blockade
(Amax) as IC50 = 122.8 WM and Amax = 96.8%.
During our experiments we observed that increasing 2-APB
concentration induced faster ICl; swell inhibition. This observa-
tion was con¢rmed by plotting the time before 50% of max-
imal ICl; swell decrease as a function of 2-APB concentration
(Fig. 2B). So time up to 50% of maximal e¡ect decreased from
132Q 24.4 to 6.5 Q 0.6 s by increasing 2-APB concentration
respectively from 20 WM to 2 mM. Such a result was consis-
tent with the idea that 2-APB would act directly on VRAC
rather than by an intermediate structure, according to the fast
inhibitory e¡ect registered with high 2-APB concentrations.
Nevertheless, we showed that 2-APB does not change the
electrophysiological properties of ICl; swell, therefore leading
Fig. 2. ICl; swell inhibition by 2-APB is a dose-dependent process. A: Dose^response relationship for the 2-APB-induced ICl; swell inhibition at
+100 mV with a superimposed ¢t of the data points (n=4) by Langmuir’s isotherm (smooth curve) and the corresponding Amax and IC50.
B: Dose^kinetics relationship for ICl; swell inhibition. Each time corresponds to the mean delay before observing 50% of the maximal ICl; swell de-
crease at the corresponding 2-APB concentration (n=4). C: E¡ect of 0.5 mM BAPTA application on ICl; swell at +100 mV in LNCaP cells
(n=5) and in LNCaP cells previously exposed to 100 WM 2-APB (n=3). D: Histogram summarizing the e¡ect of 100 WM 2-APB application
on ICl; swell at +100 mV in LNCaP cells (n=4) and in LNCaP cells pre-treated (30 min at 37‡C) with 10 mM MBCD (n=4).
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us to investigate whether it could change other properties of
ICl; swell in LNCaP cells. First, we tested the sensitivity of re-
maining ICl; swell after a 100 WM 2-APB application, and fur-
ther exposure to 0.5 mM BAPTA (Fig. 2C). In this case,
BAPTA application after the 2-APB e¡ect led to a 36.5 Q
0.7% decrease in the remaining ICl; swell at +100 mV (n=3),
i.e. nearly a two-fold decrease in the normal e¡ect recorded
when BAPTA was added alone (63.2 Q 4.9% decrease, n=5).
As a second step, we investigated 2-APB inhibitory e¡ect in
cells exposed to methyl-L-cyclodextrin (MBCD), a disrupter
of caveolae. We previously demonstrated that MBCD was
able to disorganize the SOC^VRAC interaction by uncoupling
the two channels, leading to the desensitization of VRAC
during capacitative Ca2þ entry [14]. Application of 100 WM
2-APB to fully developed ICl; swell induced a 44.4Q 3% decrease
(n=4). The corresponding decrease in cells pre-treated with
MBCD was not signi¢cantly di¡erent from the one in control
cells (49.9 Q 8.6% decrease at +100 mV, n=4), indicating that
disruption of the SOC^VRAC interaction was without e¡ect
on ICl; swell inhibition by 2-APB (Fig. 2D).
3.3. 2-APB allows separate study of VRAC and SOC
We repeated the experiments described in our previous
work [7] by applying a fully developed ICl; swell 1 WM thapsi-
gargin (Tg) to a 2 mM Ca2þ containing extracellular solution.
This experiment was shown to decrease ICl; swell amplitude by
37Q 6%. Fig. 3A presents the results obtained in the presence
of 2-APB: after complete ICl; swell development, we ¢rst added
extracellular solution 100 WM 2-APB, which induced a two-
fold decrease in ICl; swell amplitude as described above. After
steady-state inhibition by 2-APB, we applied a 100 WM
2-APB+1 WM Tg solution to the remaining ICl; swell, which
appeared to be without e¡ect. By using Ca2þ imaging, we
proved 100 WM 2-APB was su⁄cient to completely block
Tg-induced capacitative Ca2þ entry (Fig. 3B), thereby leading
us to conclude that using 2-APB at the appropriate concen-
tration could be a very useful tool to study the VRAC^SOC
interaction.
3.4. VRAC inhibition by 2-APB is not restricted to human
prostate cancer cells
In order to assess whether the 2-APB e¡ect on VRAC was
limited to human prostate cancer cells, we did further experi-
ments with a well-de¢ned keratinocyte model for which
VRACs have been previously characterized, namely the HA-
CaT cell line [15]. Like LNCaP cells, HACaT exhibits an out-
wardly rectifying chloride current when exposed to hypotonic
solution (Fig. 4A, left panel). These I/V traces show that the
current possesses, as in LNCaP cells, a slight inactivation for
potentials above +60 mV. Moreover, a 100 WM 2-APB appli-
cation induced a dramatic decrease in ICl; swell (Fig. 4A, right
panel). As illustrated in Fig. 4B, the 2-APB e¡ect is not vol-
tage dependent and for the same dose (100 WM) 2-APB ex-
hibits the same inhibitory e¡ect on ICl; swell in LNCaP cells and
HACaT: 44.4 Q 3%/52.3 Q 8.3% and 53.1Q 8.6%/63.2 Q 6.1% at
+100/3100 mV respectively (Fig. 4C).
C
Fig. 3. 2-APB completely prevents Tg-induced capacitative Ca2þ en-
try. A: Changes of ICl; swell (circles) initially evoked by hypotonic so-
lution in a representative cell ¢rst exposed to 100 WM 2-APB alone
and second with 1 WM Tg (down triangles). B: Intracellular Ca2þ
variation in cells sequentially exposed to 1 WM Tg without extracel-
lular Ca2þ and to a 1 WM Tg+2 mM Ca2þ containing isotonic
extracellular solution. Resulting traces in control (circles, n=58) or
in presence of 100 WM 2-APB (down triangles, n=65) are presented.
C: Current inhibition at +100 mV in cells exposed to 100 WM and
1 mM 2,2-diphenyltetrahydrofuran (n=3), or to 100 WM and 1 mM
2-APB (n=4).
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4. Discussion
2-APB was ¢rstly widely used in biological research for
studying the IP3 receptor and its action has been considered
as being an exclusive inhibitor of this receptor. Further stud-
ies, however, demonstrated that 2-APB is also a potent inhib-
itor of the store-operated Ca2þ channels in human platelets
[8]. The speci¢city of these inhibitors has to be relativized
according to previous observations by Gericke et al. [16],
demonstrating that the well-known VRAC inhibitor NPPB,
was also a quite e¡ective inhibitor of Ca2þ channels in human
endothelial cells. Moreover, it was recently shown that 2-APB
may block voltage-dependent potassium channels in Limulus
ventral photoreceptors [9] and gap junctional coupling in nor-
mal rat kidney cells [17].
Our study clearly establishes that 2-APB is an inhibitor of
volume-dependent chloride channels. This observation seems
to be a general feature of VRACs since we observed the same
inhibitory e¡ect on VRACs using two cellular models : pros-
tate cancer epithelial cell and keratinocytes. This e¡ect may
result either from direct interaction between 2-APB and the
VRAC or from the interaction of 2-APB with an intermediate
target that in turn may inhibit the VRAC activity. However, it
seems very unlikely that this 2-APB inhibitory e¡ect on
VRAC may involve one of its previously reported actions.
Indeed, the hypothesis that 2-APB interacts with the VRAC
both directly and di¡erentially from its other targets was con-
¢rmed by experiments using DPTHF, a compound structur-
ally similar to 2-APB. DPTHF has indeed previously been
reported to mimic 2-APB e¡ects, in particular by inhibiting
IP3 receptors. Nevertheless, DPTHF application was shown in
this study to be ine¡ective on VRAC current. Moreover,
BAPTA, which was suggested to block VRAC activity by
direct binding the channel, exhibited a reduced e¡ect after
2-APB application. This observation is compatible with a
competition between BAPTA and 2-APB to bind the VRAC.
Finally, our results indicate that ICl; swell blockade by 2-APB
is not speci¢c to the human prostate epithelial cells, but may
represent a general phenomenon independent of the cell type.
We therefore suggest using 2-APB with caution, which implies
carefully studying the VRAC^SOC^IP3 receptor interactions
in order to avoid any incorrect interpretations.
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Fig. 4. 2-APB exhibits the same properties for VRAC current in keratinocytes as in LNCaP cells. A: ICl; swell traces obtained in HACaT in con-
trol conditions (left) and after 100 WM 2-APB application (right). Pulse protocol is presented in the inset. B: I/V relationship derived from
ramp traces shown as inset in control (ctrl) or after 100 WM 2-APB (2-APB). C: Histogram summarizing the e¡ect of 100 WM 2-APB on
VRAC current in LNCaP cells (n=4) and in HACaT (n=6).
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